Consolidated Financial Highlights for the Financial Year2023-24(In INR Mn)
|
Particulars |
March 31, 2024 |
March 31, 2023 |
YoY Growth |
|
Revenue from operations |
25,896 |
23,061 |
12.3% |
|
312.8 |
287.5 |
8.8% |
|
|
EBITDA |
5,841 |
4,542 |
28.6% |
|
Profit before tax |
4,586 |
3,630 |
26.3% |
|
Profit after tax |
3,367 |
2,661 |
26.5% |
Consolidated Financial Highlights for the Quarter endedMarch 31, 2024
(In INR Mn)
|
Particulars |
Q4FY24 |
YoY Growth |
QoQ Growth |
|
Revenue from operations |
6,730 |
6.5% |
–0.1% |
|
Revenue from operations ($ Mn) |
81.1 |
5.2% |
0.1% |
|
EBITDA |
1,643 |
48.7% |
1.4% |
|
Profit before tax |
1,336 |
68.7% |
1.0% |
|
Profit after tax |
949 |
94.6% |
–3.9% |
Manish Gupta, Chairman and Chief Executive Officer – “We are pleased with our continued performance this quarter and the full year. Today in the marketplace we are known as a digital first commercialization partner to the global life sciences industry. We have 63 active clients and work with all the top 20 global pharmaceutical companies. Our revenues very closely mirrors the global life sciences industry’s spends on operations. 69% of our revenues come from the top 20 Pharma companies. Global LifeSciences industry is more than USO 1.8 Tn Industry. We are excited about the opportunity in front of us.”
Suhas Prabhu, Chief Financial Officer – “Our financial results reflect our focus on operational excellence, cost optimization and value-driven service delivery. While revenue grew steadily, we delivered strong growth in margins, with a healthy cash conversion and a strong balance sheet, providing us with the flexibility toinvest in growth opportunities. We remain committed to delivering value to our clients and shareholders through deep domain expertise, innovation and operational excellence.”
